Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
System1 Biosciences
AddedFeb 15, 2024
UpdatedJun 18, 2026
System1 Biosciences

System1 Biosciences

System1 Biosciences, a neurotherapeutics firm, uses advanced tech to discover drugs for complex neurological disorders.

HQ
San Francisco, CA, US
Founded
2017
Overview
Compare
Fundraising
Employees

System1 Biosciences, a neurotherapeutics firm based in San Francisco, employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases like epilepsy, autism, and schizophrenia. The company integrates cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to achieve unprecedented disease characterizations.

System1 Biosciences has made significant strides in drug discovery, leveraging cutting-edge technology to address disorders that traditional methods have struggled with. Their innovative approach has positioned them as a leader in the neurotherapeutics field, driving impactful advancements in the treatment of neurological conditions.

System1 Biosciences - Similar Companies

MapLight Therapeutics logo

MapLight Therapeutics

NeuroTherapeutics Pharma logo

NeuroTherapeutics Pharma

Neurolink logo

Neurolink

Intellect Neurosciences logo

Intellect Neurosciences

VersaPeutics logo

VersaPeutics

Seven Biosciences logo

Seven Biosciences

Bios Health logo

Bios Health

bios.health

Actio Biosciences logo

Actio Biosciences

actiobio.com

Boundless Bio logo

Boundless Bio

Scioto Biosciences logo

Scioto Biosciences

Enveda Biosciences logo

Enveda Biosciences

envedabio.com

Khloris Biosciences logo

Khloris Biosciences

Terremoto Biosciences logo

Terremoto Biosciences

terremotobio.com

PhenoVista Biosciences logo

PhenoVista Biosciences

phenovista.com

Retro Biosciences logo

Retro Biosciences

retro.bio

System1 Biosciences - Quick Facts

Who are System1 Biosciences' competitors?

Companies similar to System1 Biosciences include MapLight Therapeutics, NeuroTherapeutics Pharma, Neurolink and Intellect Neurosciences.

When was System1 Biosciences founded?

System1 Biosciences was founded in 2017.

Where is System1 Biosciences' headquarters located?

System1 Biosciences' headquarters is located in San Francisco, CA, US.

When was System1 Biosciences' last funding round?

System1 Biosciences' most recent funding round was for $25M (USD) in September 2018.

How much has System1 Biosciences raised to-date?

As of Sep 12, 2018, System1 Biosciences has raised a total of $25M (USD).

How many employees does System1 Biosciences have?

System1 Biosciences has 30 employees as of Feb 4, 2024.

System1 Biosciences - Classification

Ownership
  • Equity
  • Venture Capital
Technology
  • AI
  • Analytics
  • Machine Learning
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drugs
  • Neurotherapeutics
Tags
  • Biotech
  • Data Information
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software